TERAZOSIN HYDROCHLORIDE by Novartis is clinical pharmacology pharmacodynamics a. Approved for symptomatic benign prostatic hyperplasia (bph), hypertension. First approved in 1998.
Drug data last refreshed 2h ago
CLINICAL PHARMACOLOGY Pharmacodynamics A. Benign Prostatic Hyperplasia (BPH) The symptoms associated with BPH are related to bladder outlet obstruction, which is comprised of two underlying components: a static component and a dynamic component. The static component is a consequence of an increase…
Worked on TERAZOSIN HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.